Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010 Dec; 104(6):1150-7.
View in:
PubMed
subject areas
Administration, Oral
Administration, Oral
Adult
Adult
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Anticoagulants
Anticoagulants
Arthroplasty, Replacement, Knee
Arthroplasty, Replacement, Knee
Canada
Canada
Dose-Response Relationship, Drug
Dose-Response Relationship, Drug
Double-Blind Method
Double-Blind Method
Elective Surgical Procedures
Elective Surgical Procedures
Enoxaparin
Enoxaparin
Factor Xa Inhibitors
Factor Xa Inhibitors
Female
Female
Hemorrhage
Hemorrhage
Humans
Humans
Logistic Models
Logistic Models
Male
Male
Middle Aged
Middle Aged
Phlebography
Phlebography
Pulmonary Embolism
Pulmonary Embolism
Pyrimidinones
Pyrimidinones
Risk Assessment
Risk Assessment
Risk Factors
Risk Factors
Sulfones
Sulfones
Time Factors
Time Factors
United States
United States
Venous Thromboembolism
Venous Thromboembolism
Venous Thrombosis
Venous Thrombosis
authors with profiles
Gary E Raskob